BETAAccess all features while we're in beta! Some features may become paid later.Send feedback →
vpside

COR

Cencora, Inc.
NYSE · Wholesale · Drugs, proprietaries & druggists' sundries (SIC 5122) · FY ends 30 Sep

Revenue, quarterly

$84.75B+5.1% year on year
$100B$50B$0
Q4 ’21Q1 ’23Q2 ’24Q2 ’25Q3 ’26
Company filings · 10-Q filed 5 Aug 2026 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

4.0%+0.5 pp year on year
4%3.8%3.5%3.3%3%
Q4 ’21Q1 ’23Q2 ’24Q2 ’25Q3 ’26
Company filings · 10-Q filed 5 Aug 2026 · TTM = last four quartersvpside.com

Cash and cash equivalents, quarter-end

$2.82B+26.1% year on year
$6B$4B$2B$0
Q4 ’21Q1 ’23Q2 ’24Q2 ’25Q3 ’26
Company filings · 10-Q filed 5 Aug 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

$4.06B+255.7% year on year
$6B$4B$2B$0−$2B
Q4 ’21Q1 ’23Q2 ’24Q2 ’25Q3 ’26
Company filings · 10-Q filed 5 Aug 2026 · TTM = last four quartersvpside.com
Chart 05 is empty
Chart 06 is empty